News
We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...
Paris: Sanofi has announced the completion of its acquisition of Blueprint Medicines Corporation, adding to its portfolio a ...
Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...
The deal with Blueprint, a Cambridge, Mass.-based immunology-disease specialist, is set to give Sanofi ownership over both an approved drug and an early-stage immunology pipeline, the companies said.
Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...
According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...
3d
Pharmaceutical Technology on MSNSanofi to acquire Vicebio’s share capital for $1.15bn upfront
Sanofi has signed an agreement to acquire UK-based biotechnology company Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities. The deal also includes additional ...
French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...
Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...
4d
Capital Brief on MSNSanofi to buy Vicebio in US$1.6b deal for Aussie-developed vaccine tech
Sanofi is acquiring UK biotechnology company Vicebio for up to US$1.6 billion ($2.4 billion) in the largest deal involving a ...
In a blockbuster pharma merger that shook the global biotech sector, Sanofi announced Friday it has officially completed its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results